Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Botulinum Toxin A - Open Label Clear all
Completed Phase 3 Interventional Results available

A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

NCT05134649
View directory record Official record
Conditions
Platysma Prominence
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Glendale, Arizona • Scottsdale, Arizona • Encino, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia

NCT01753336
View directory record Official record
Conditions
Cervical Dystonia
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Results available

Dysport® Adult Upper Limb Spasticity Extension Study

NCT01313312
View directory record Official record
Conditions
Nervous System Disorders
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Sep 7, 2026, 9:43 PM EDT
Not listed Early Phase 1 Interventional

Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome

NCT05485207
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Transvaginal botulinum toxin A (BTA) injection
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 1 Interventional

Hyperhidrosis in Patients With Amputations-Botox

NCT03236012
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Toxin Type A (Botox)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 3 Interventional

A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants

NCT06399718
View directory record Official record
Conditions
Masseter Muscle Prominence
Interventions
BOTOX, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Angeles, California • Newport Beach, California • Vista, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 7, 2026, 9:43 PM EDT
Not listed Phase 1 Interventional

New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain

NCT02008136
View directory record Official record
Conditions
Cervicalgia, Low Back Pain
Interventions
Botulinum Toxins
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 7, 2026, 9:43 PM EDT
Not listed Not applicable Interventional

Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome

NCT02187679
View directory record Official record
Conditions
Tourette Syndrome, Chronic Vocal Tic
Interventions
Abobotulinum toxin A
Drug
Lead sponsor
Detroit Clinical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Results available

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

NCT00406367
View directory record Official record
Conditions
Blepharospasm
Interventions
incobotulinumtoxinA (Xeomin), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Subject Satisfaction With AbobutulinumtoxinA Treatment

NCT03687736
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety Study of Botulinum Neurotoxin A With Rehabilitation Versus Botulinum Neurotoxin A Alone in Treatment of Post-stroke Spasticity

NCT00945295
View directory record Official record
Conditions
Upper Limb Spasticity
Interventions
Botulinum toxin type A, BoNT-A, Rehabilitation Therapy
Drug · Other
Lead sponsor
JoAnn Harnar
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 7, 2026, 9:43 PM EDT
Not listed No phase listed Observational

Open Label, 6-month Study for High Frequency and Chronic Migraine,

NCT06133491
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
Daxibotulinumtonix A
Biological
Lead sponsor
Ki Health Partners. LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Early Phase 1 Interventional

The Effect of Botulinum Toxin A on Headache Attributed to TMD

NCT03346252
View directory record Official record
Conditions
Secondary Headache Disorder
Interventions
Botulinum Toxin type A
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 74 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles

NCT05162300
View directory record Official record
Conditions
Photoaging, Wrinkle, Sun Damaged Skin
Interventions
Same Day Intervention of VI Peel (Procedure) and Botulinum Toxin (Drug)
Combination Product
Lead sponsor
Vitality Institute Medical Products
Industry
Eligibility
30 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rancho Mirage, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 7, 2026, 9:43 PM EDT
Terminated Phase 2 Interventional

OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study

NCT01920945
View directory record Official record
Conditions
New Daily Persistent Headache
Interventions
OnabotulinumtoxinA
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines

NCT03911102
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
DaxibotulinumtoxinA for injection
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Sacramento, California • Sarasota, Florida • Itasca, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 2 Interventional Results available

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

NCT05013424
View directory record Official record
Conditions
Glabellar Lines
Interventions
Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Glendale, Arizona • Coral Gables, Florida • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Results available

Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

NCT03004248
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxins, Type A
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 7, 2026, 9:43 PM EDT
Terminated Phase 3 Interventional

Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

NCT01818076
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines

NCT04631588
View directory record Official record
Conditions
Facial Fine Lines
Interventions
Botox, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
Miami, Florida • New York, New York • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

NCT02677298
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Croma-Pharma GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
784 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Encino, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 4 Interventional Results available

Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia

NCT00208091
View directory record Official record
Conditions
Focal Dystonia
Interventions
Botulinum toxin, type B
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 69 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

NCT02261467
View directory record Official record
Conditions
Forehead Rhytides, Glabellar Rhytides
Interventions
OnabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Birmingham, Alabama • Glendale, Arizona • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 7, 2026, 9:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability and Immunogenicity of Recombinant Botulinum Vaccine A/B in Healthy Adults

NCT00098098
View directory record Official record
Conditions
RECOMBINANT BOTULINUM VACCINE A/B
Interventions
rBV A/B
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 40 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 22, 2012 · Synced Sep 7, 2026, 9:43 PM EDT